Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

REGN

Regeneron Pharmaceuticals, Inc

Oct 31 • 04:00PM ET

651.80

-2.24 -0.34 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI QQQ VOO IVV SPY VTV XLV IBB JEPI COWZ

Scroll to Statements

Index	NDX, S&P 500	P/E	15.60	EPS (ttm)	41.77	Insider Own	3.63%	Shs Outstand	103.50M	Perf Week	12.78%
Market Cap	68.49B	Forward P/E	15.26	EPS next Y	42.71	Insider Trans	-0.17%	Shs Float	101.27M	Perf Month	8.63%
Enterprise Value	62.75B	PEG	4.66	EPS next Q	10.56	Inst Own	86.55%	Short Float	2.89%	Perf Quarter	14.04%
Income	4.58B	P/S	4.81	EPS this Y	-5.75%	Inst Trans	-3.40%	Short Ratio	2.71	Perf Half Y	7.63%
Sales	14.25B	P/B	2.22	EPS next Y	-0.66%	ROA	11.80%	Short Interest	2.93M	Perf YTD	-8.50%
Book/sh	294.00	P/C	8.11	EPS next 5Y	3.35%	ROE	15.19%	52W High	883.15 -26.20%	Perf Year	-29.71%
Cash/sh	80.42	P/FCF	16.22	EPS past 3/5Y	-18.94% 15.74%	ROIC	13.60%	52W Low	476.49 36.79%	Perf 3Y	-11.20%
Dividend Est.	3.08 (0.47%)	EV/EBITDA	14.41	Sales past 3/5Y	-4.04% 16.71%	Gross Margin	81.71%	Volatility	3.82% 3.20%	Perf 5Y	11.28%
Dividend TTM	2.64 (0.41%)	EV/Sales	4.40	EPS Y/Y TTM	0.50%	Oper. Margin	26.88%	ATR (14)	19.57	Perf 10Y	21.45%
Dividend Ex-Date	Nov 20, 2025	Quick Ratio	3.33	Sales Y/Y TTM	2.89%	Profit Margin	32.13%	RSI (14)	71.65	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	4.06	EPS Q/Q	18.05%	SMA20	10.34%	Beta	0.31	Target Price	756.65
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	0.90%	SMA50	12.00%	Rel Volume	0.74	Prev Close	654.04
Employees	15106	LT Debt/Eq	0.09	Earnings	Oct 28 BMO	SMA200	9.31%	Avg Volume	1.08M	Price	651.80
IPO	Apr 02, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.53% 4.51%	Trades		Volume	797,907	Change	-0.34%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy	$890
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976

Show Previous Ratings

Oct-31-25 08:37AM	AstraZenecas gMG drug fails to fend off rivals despite Phase III win (Clinical Trials Arena)
07:00AM	Dupixent (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award (GlobeNewswire)
Oct-30-25 07:14PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Oct-29-25 03:29PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
12:11PM	Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher? (Barrons.com)
08:49AM	Loading…
08:49AM	FDA rejects Regenerons pre-filled Eylea HD syringes amid filling facility woes (Pharmaceutical Technology)
01:32AM	REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage (StockStory)
12:03AM	Market Wrap: Top Stock Movers- PayPal, Nokia, and Wayfair (TheStreet)
Oct-28-25 03:03PM	REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase (Zacks) +11.82%
12:11PM	Why Are Regeneron (REGN) Shares Soaring Today (StockStory)
12:10PM	Nvidia investing $1B in Nokia, Trump admin. inks nuclear deal (Yahoo Finance Video)
09:30AM	Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics (Zacks)
09:01AM	Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts (Investor's Business Daily)
07:58AM	Regeneron (NASDAQ:REGN) Surprises With Strong Q3 (StockStory)
07:40AM	Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
07:06AM	Loading…
07:06AM	Regeneron earnings beat estimates amid strong anti-inflammatory drug demand (Investing.com)
06:40AM	Regeneron: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Regeneron Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Oct-26-25 11:13PM	Regeneron Earnings: What To Look For From REGN (StockStory)
07:25AM	European Medicines Agency Adopts a Positive Opinion on ?Regeneron's (REGN) Libtayo (Insider Monkey)
Oct-24-25 07:03PM	Analyst Report: Sanofi (Morningstar Research)
04:12PM	Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue (Investor's Business Daily)
03:19PM	Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week (The Wall Street Journal)
01:14PM	Long Leaf Partners Fund's Comment on Regeneron (REGN) (Insider Monkey)
10:01AM	Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline (Zacks)
09:56AM	REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? (Zacks)
02:55AM	Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance (The Wall Street Journal)
Oct-23-25 09:15AM	Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS (Zacks)
09:05AM	RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised (Zacks)
Oct-21-25 10:00AM	Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline (Zacks)
09:25AM	Loading…
Oct-20-25 09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks)
Oct-17-25 04:21PM	The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. (Investor's Business Daily)
07:30AM	Libtayo (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation (GlobeNewswire)
Oct-16-25 02:54AM	REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised) (Zacks)
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
07:00AM	Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers (GlobeNewswire)
Oct-14-25 10:49AM	Regenerons Q3 2025 Earnings: What to Expect (Barchart)
10:00AM	2 Stocks Down 17% and 21% to Buy Right Now (Motley Fool)
Oct-13-25 10:02AM	REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Zacks)
09:44AM	Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge (Insider Monkey)
09:41AM	Stock Market Today: Dow Jumps 400 Points On Trump Tariff Comments; Broadcom, Nvidia, Tesla Rally (Live Coverage) (Investor's Business Daily)
Oct-12-25 10:18AM	DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss (GlobeNewswire)
06:18AM	Regeneron, with game-changing new data, to seek approval of hearing loss gene therapy (BioPharma Dive)
Oct-09-25 04:08PM	Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out (Investor's Business Daily)
09:15AM	Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo (Zacks)
07:23AM	Regeneron, needing a turnaround, gains new use for cancer drug (BioPharma Dive)
Oct-08-25 02:31PM	Libtayo (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation (GlobeNewswire)
Oct-07-25 11:49AM	11 Cheap Stocks for a Market That's Too Expensive (Barrons.com)
Oct-06-25 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-02-25 04:55PM	Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management (Insider Monkey)
09:45AM	Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough (Insider Monkey)
Oct-01-25 08:10PM	Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials (Insider Monkey) +6.70%
02:16AM	Regeneron's Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5 (Insider Monkey)
Sep-30-25 04:05PM	Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 (GlobeNewswire)
07:30AM	2 Beaten-Down Stocks to Buy and Hold for a Decade (Motley Fool)
Sep-29-25 02:53PM	Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease (Insider Monkey)
10:43AM	Here's Why Regeneron Pharmaceuticals (REGN) Fell in Q2 (Insider Monkey)
08:28AM	FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza (Zacks)
06:02AM	Regenerons Evkeeza gains FDA approval for young HoFH patients (Pharmaceutical Technology)
12:36AM	1 Healthcare Stock with Exciting Potential and 2 We Ignore (StockStory)
Sep-26-25 07:00AM	Evkeeza (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol (GlobeNewswire)
Sep-25-25 04:51PM	Why Regeneron (REGN) Shares Are Falling Today (StockStory)
Sep-24-25 01:57AM	Regeneron's Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide (Insider Monkey)
Sep-23-25 03:26PM	Why Regeneron (REGN) Stock Is Down Today (StockStory)
09:45AM	Stock Market Today: Dow Up Ahead Of Powell Speech; Nvidia At Buy Point (Live Coverage) (Investor's Business Daily)
07:11AM	US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall (Reuters)
Sep-22-25 12:03PM	SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU (Zacks)
09:35AM	Humana initiated, Paycom upgraded: Wall Street's top analyst calls (The Fly)
12:29AM	Dupixent (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion (GlobeNewswire)
Sep-19-25 01:17PM	Can Regeneron Change The Paradigm In Multiple Myeloma - And Undercut J&J? (Investor's Business Daily)
12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
07:06AM	Arvinas reboots, cuts more staff; Porges joins Lazard (BioPharma Dive)
07:00AM	Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks (GlobeNewswire)
Sep-18-25 12:02AM	3 Reasons to Sell REGN and 1 Stock to Buy Instead (StockStory)
Sep-17-25 02:27PM	Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies (Insider Monkey)
09:30AM	Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD (GlobeNewswire)
07:00AM	Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation (GlobeNewswire)
Sep-16-25 12:30PM	Kymera initiated at Outperform on potential of lead skin drug (Investing.com)
12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
11:42AM	Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial (Insider Monkey)
Sep-15-25 09:53AM	REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock? (Zacks)
08:15AM	BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN) (Insider Monkey)
Sep-14-25 01:17AM	BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT (Insider Monkey)
Sep-12-25 08:33AM	Maias NSCLC immunotherapy secures Phase II efficacy win (Clinical Trials Arena)
Sep-11-25 12:55PM	Phase III success for Regeneron signals pozelimab and cemdisirans entry into MG market (Clinical Trials Arena)
04:57AM	Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? (Zacks)
Sep-10-25 07:33AM	Kriya, Odyssey secure megarounds; Amgen boosts R&D leadership (BioPharma Dive)
04:00AM	Pharmas new boomtown? Why drugmakers are setting up shop in a small Swiss city. (Pharma Voice)
Sep-09-25 03:10PM	Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy (Benzinga)
12:38PM	Regenerons cat and birch allergy mAbs score in Phase III trials (Clinical Trials Arena)
12:28PM	Health Care Roundup: Market Talk (The Wall Street Journal)
07:00AM	Libtayo (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer (GlobeNewswire)
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks)
06:30AM	Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies (GlobeNewswire)
Sep-07-25 09:15AM	2 Beaten-Down Stocks to Buy on the Dip (Motley Fool)
Sep-05-25 10:11AM	RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress (Zacks)
Sep-04-25 04:05PM	Regeneron Announces Updated Presentation Time for Upcoming Investor Conference (GlobeNewswire)
01:32PM	Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory (Insider Monkey)
10:48AM	SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study (Zacks)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
POON CHRISTINE A	Director	Oct 29 '25	Option Exercise	520.01	6,500	3,380,065	8,852	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 30 '25	Option Exercise	520.01	2,712	1,410,267	5,064	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 29 '25	Sale	654.27	6,500	4,252,745	2,352	Oct 31 04:09 PM
MURPHY ANDREW J	EVP Research	Oct 29 '25	Option Exercise	555.67	35,000	19,448,450	84,074	Oct 31 04:06 PM
Christine Poon	Director	Oct 29 '25	Proposed Sale	652.91	6,500	4,243,915		Oct 29 04:36 PM
SING GEORGE L	Director	Dec 31 '24	Option Exercise	413.33	3,338	1,379,696	29,610	Jan 03 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience